OR-1855 |
Katalog-Nr.GC39260 |
OR-1855, ein aktiver Metabolit von Levosimendan, wirkt sich auf die KontraktilitÄt des menschlichen Myometriums aus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 101328-85-2
Sample solution is provided at 25 µL, 10mM.
OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure[1][2].
[1]. Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. [2]. Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *